REMSleep Holdings Inc. Announces Strategic Marketing Plan for DELTAWAVE Nasal Pillows System
CLEARWATER, Fla., July 17, 2024 (GLOBE NEWSWIRE) -- REMSleep Holdings Inc. (OTCQB: RMSL), a pioneer in sleep apnea treatment solutions,...
News
On Heels of Family Forward NC Certification, Aeroflow Health Will Employ a Record 900 in Coming Months
ASHEVILLE, N.C., July 17, 2024 (GLOBE NEWSWIRE) -- Aeroflow Health announced today that it has made its 850th hire and...
Yield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Assets for Producing Oil in Camelina, and Yield10 and Nufarm sign a Memorandum of Understanding for Sale of Assets
- Nufarm to pay up to USD $5 million in consideration for the license-The parties will negotiate the sale of...
Globus Medical Receives FDA 510(k) Clearance for ExcelsiusFlex™ and ACTIFY™ 3D Total Knee System
AUDUBON, Pa., July 17, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced...
Kane Biotech Receives ISO 13485:2016 MDSAP Quality Certification
Provides access to Canadian, Australian, New Zealand and Brazilian marketsWINNIPEG, Manitoba, July 17, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc....
Bon Secours Mercy Health and Philips sign multi-year strategic collaboration
Doctor monitoring patient health July 17, 2024 Patient monitoring platform to deliver tools and time to help patients across 40+...
Standard BioTools Announces Conference Call and Webcast for Second Quarter 2024 Financial Results on July 31, 2024
SOUTH SAN FRANCISCO, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB)...
Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host...
CervoMed to Participate in the Emerging Growth Conference
BOSTON, July 17, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for...
Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives
Rick Barry appointed Executive Chairman of the BoardRemi Barbier resigns as President and CEO and from the Board of DirectorsCassava...
What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk
New Nationwide Survey Findings Show That More Than Half of Women Do Not Know That Breast Density Can Reveal Increased...
HealthLynked Expands Telemedicine Nationwide
NAPLES, Fla., July 17, 2024 (GLOBE NEWSWIRE) -- via IBN – HealthLynked Corp. (OTCQB: HLYK), a global leader in healthcare...
MIMEDX to Host Second Quarter 2024 Operating and Financial Results Conference Call on July 31
MARIETTA, Ga., July 17, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that...
Processa Pharmaceuticals Names Russell L. Skibsted as Chief Financial Officer
HANOVER, Md., July 17, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical...
STRATA Skin Sciences’ TheraClear®X Acne Therapy System Found Safe and Effective in Study Published in Peer Reviewed Journal
Study published in Journal of Cosmetic and Laser Therapy highlights the TheraClear®X photopneumatic device as an effective treatment option, either...
Longeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B™ for the Treatment of Mild Alzheimer’s Disease
Wa'el Hashad Wa'el Hashad, CEO, Longeveron – FDA designation enables expedited clinical development and regulatory review timelines for Lomecel-B™ – –...
Immutep Receives Regulatory Clearance for Phase I Study of First-in-Class LAG-3 Agonist Antibody Designed to Treat Autoimmune Diseases
Media Release Study expected to enrol first participants during Q3 CY2024 SYDNEY, AUSTRALIA, July 17, 2024 (GLOBE NEWSWIRE) -- Immutep...
Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease at the Alzheimer’s Association International Conference, Philadelphia, July 31, 2024
Pepinemab is believed to block astrocyte reactivity, a key pathology driving Alzheimer’s progressionROCHESTER, N.Y., July 17, 2024 (GLOBE NEWSWIRE) --...
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had...
ASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation of Its Sole Operating Subsidiary and is Commencing Steps to Place Itself Into Voluntary Liquidation
Following a thorough review of all strategic alternatives, ASLAN Pharmaceuticals Pte Ltd, the sole operating subsidiary of ASLAN Pharmaceuticals, has...